These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32519171)
21. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063 [TBL] [Abstract][Full Text] [Related]
22. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F; Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538 [TBL] [Abstract][Full Text] [Related]
23. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031 [TBL] [Abstract][Full Text] [Related]
24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467 [TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436 [TBL] [Abstract][Full Text] [Related]
26. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. Jo JC; Kim SJ; Lee HS; Eom HS; Lee SI; Park Y; Lee JO; Lee Y; Yhim HY; Yang DH; Byun JM; Kang HJ; Kim HJ; Shin HJ; Yoo KH; Suh C; Ann Hematol; 2020 Feb; 99(2):223-228. PubMed ID: 31853704 [TBL] [Abstract][Full Text] [Related]
27. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab]. Kanaji N; Ishibashi K; Uno H; Hino N Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience. Bhatt VR; Loberiza FR; Smith LM; Armitage JO; Greiner TC; Bast M; Lunning MA; Bierman PJ; Vose JM; Bociek RG Leuk Lymphoma; 2016; 57(6):1327-34. PubMed ID: 26377137 [TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma: a Turkish Multi-Center Study. Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879 [TBL] [Abstract][Full Text] [Related]
30. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP; Khoury HJ; Langston AA Bone Marrow Transplant; 2008 Oct; 42(8):529-34. PubMed ID: 18622414 [TBL] [Abstract][Full Text] [Related]
31. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Andersen NS; Pedersen L; Elonen E; Johnson A; Kolstad A; Franssila K; Langholm R; Ralfkiaer E; Akerman M; Eriksson M; Kuittinen O; Geisler CH; Eur J Haematol; 2003 Aug; 71(2):73-80. PubMed ID: 12890145 [TBL] [Abstract][Full Text] [Related]
32. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667 [TBL] [Abstract][Full Text] [Related]
34. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540 [TBL] [Abstract][Full Text] [Related]
36. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467 [TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang M; Cohen JB; Churnetski M; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast M; Fenske T; Rao Gari SN; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns T; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Ristow K; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK Blood Adv; 2023 Dec; 7(24):7393-7401. PubMed ID: 37874912 [TBL] [Abstract][Full Text] [Related]
38. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma? Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895 [TBL] [Abstract][Full Text] [Related]
39. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717 [TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]